Catalog No.
RVV19926
Species reactivity
Dengue virus type 2 (strain Peru/IQT2913/1996) (DENV-2)
Host species
Human
Isotype
IgG1, kappa
Clonality
Monoclonal
Target
Genome polyprotein, Envelope protein E
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9WDA6
Applications
FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
E53#
Efficient generation and characterization of chimeric dengue viral-like particles., PMID:36878035
Recombinant Protein Mimicking the Antigenic Structure of the Viral Surface Envelope Protein Reinforces Induction of an Antigen-Specific and Virus-Neutralizing Immune Response Against Dengue Virus., PMID:36723792
Reactivity of DENV-positive sera against recombinant envelope proteins produced in bacteria and eukaryotic cells., PMID:36192522
Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement., PMID:32305868
Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine., PMID:32300346
Aedes aegypti lachesin protein binds to the domain III of envelop protein of Dengue virus-2 and inhibits viral replication., PMID:32141690
Potent Zika and dengue cross-neutralizing antibodies induced by Zika vaccination in a dengue-experienced donor., PMID:32015557
The Dengue ED3 Dot Assay, a Novel Serological Test for the Detection of Denguevirus Type-Specific Antibodies and Its Application in a Retrospective Seroprevalence Study., PMID:30934772
Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice., PMID:29976679
Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo., PMID:29367852
Safe Staphylococcal Platform for the Development of Multivalent Nanoscale Vesicles against Viral Infections., PMID:29253342
A DENV-2-type-specific monoclonal antibody binds to the DENV-complex-reactive antigenic site on envelope protein domain 3., PMID:28631593
Understanding Zika Virus Stability and Developing a Chimeric Vaccine through Functional Analysis., PMID:28174309
Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies., PMID:27301568
Characterization of two anti-dengue human monoclonal antibodies prepared from PBMCs of patients with dengue illness in Thailand., PMID:27265466
Recombinant Dengue 2 Virus NS3 Helicase Protein Enhances Antibody and T-Cell Response of Purified Inactivated Vaccine., PMID:27035715
Actin Interacts with Dengue Virus 2 and 4 Envelope Proteins., PMID:27010925
[Mapping of the B Cell Neutralizing Epitopes on ED III of Envelope Protein from Dengue Virus]., PMID:26951013
Characterization of N-Glycan Structures on the Surface of Mature Dengue 2 Virus Derived from Insect Cells., PMID:26208004
Selection and Characterization of DNA Aptamers Targeting All Four Serotypes of Dengue Viruses., PMID:26110785
Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys., PMID:25761459
DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice., PMID:23880886
Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection., PMID:23785205
Sulfated polysaccharide, curdlan sulfate, efficiently prevents entry/fusion and restricts antibody-dependent enhancement of dengue virus infection in vitro: a possible candidate for clinical application., PMID:23658845
Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes., PMID:23331315
Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibody-dependent enhancement., PMID:22709350
Development of a humanized antibody with high therapeutic potential against dengue virus type 2., PMID:22563515
Eliciting cross-neutralizing antibodies in mice challenged with a dengue virus envelope domain III expressed in Escherichia coli., PMID:22420529
Conservation of the DENV-2 type-specific and DEN complex-reactive antigenic sites among DENV-2 genotypes., PMID:22153298
Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses., PMID:21419774
Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2., PMID:20592088
Structural optimization and de novo design of dengue virus entry inhibitory peptides., PMID:20582308
Characterization of a dengue type-specific epitope on dengue 3 virus envelope protein domain III., PMID:20444995
Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens., PMID:19337372
Characterization of dengue complex-reactive epitopes on dengue 3 virus envelope protein domain III., PMID:19101005
Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus., PMID:18562544
Use of synthetic peptides to represent surface-exposed epitopes defined by neutralizing dengue complex- and flavivirus group-reactive monoclonal antibodies on the native dengue type-2 virus envelope glycoprotein., PMID:18559931
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes., PMID:17881453
Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus., PMID:17719070
Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques., PMID:16973561
Epitope determinants of a chimpanzee Fab antibody that efficiently cross-neutralizes dengue type 1 and type 2 viruses map to inside and in close proximity to fusion loop of the dengue type 2 virus envelope glycoprotein., PMID:15542644
For research use only. Not for human or drug use.
